Efficacy of first line of bevacizumab in patients with neurofibromatosis 2-related vestibular schwannomas

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F25%3A10503790" target="_blank" >RIV/00064203:_____/25:10503790 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/25:10503790 RIV/00216208:11130/25:10503790

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=NZ7NmgV0MC" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=NZ7NmgV0MC</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s00405-025-09734-w" target="_blank" >10.1007/s00405-025-09734-w</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Efficacy of first line of bevacizumab in patients with neurofibromatosis 2-related vestibular schwannomas

Popis výsledku v původním jazyce

PURPOSE: NF2-related schwannomatosis (NF2) patients are predisposed to develop multiple peripheral and central nervous tumors including bilateral vestibular schwannomas (VS). Decision on patient management, especially in large growing tumors, might be challenging concerning possible treatment-related complications and quality of life. Systemic therapy with bevacizumab has been reported to slow VS growth and improve hearing. Here, we present single-center outcomes of NF2 patients treated with bevacizumab. METHODS: We conducted a retrospective analysis of 15 NF2 patients with morphologically diagnosed unilateral or bilateral VS indicated for systemic therapy with bevacizumab (5 mg/kg every 2 weeks) in 2015-2022. Tumor growth rate, volume, and hearing thresholds were assessed before, during, and after first-line bevacizumab therapy. RESULTS: 15 patients (5 male, 10 females, mean age at the start of the therapy 30y, mean no. of bevacizumab cycles 35) and 25 tumors were evaluated. Radiologically significant (&gt; 20% from the baseline) tumor volume reduction was observed in 5 patients. Notably, in patients with bilateral VS, volume reduction occurred on only one side. Three patients demonstrated a significantly reduced growth rate and tumor stabilization. Hearing improvement was documented in 1 patient, while another experienced significant hearing decline. CONCLUSION: Bevacizumab therapy may contribute to tumor shrinkage and hearing stabilization in NF2 patients. However, treatment response is variable, with meaningful tumor reduction and hearing improvement observed only in a minority of cases.

Název v anglickém jazyce

Efficacy of first line of bevacizumab in patients with neurofibromatosis 2-related vestibular schwannomas

Popis výsledku anglicky

PURPOSE: NF2-related schwannomatosis (NF2) patients are predisposed to develop multiple peripheral and central nervous tumors including bilateral vestibular schwannomas (VS). Decision on patient management, especially in large growing tumors, might be challenging concerning possible treatment-related complications and quality of life. Systemic therapy with bevacizumab has been reported to slow VS growth and improve hearing. Here, we present single-center outcomes of NF2 patients treated with bevacizumab. METHODS: We conducted a retrospective analysis of 15 NF2 patients with morphologically diagnosed unilateral or bilateral VS indicated for systemic therapy with bevacizumab (5 mg/kg every 2 weeks) in 2015-2022. Tumor growth rate, volume, and hearing thresholds were assessed before, during, and after first-line bevacizumab therapy. RESULTS: 15 patients (5 male, 10 females, mean age at the start of the therapy 30y, mean no. of bevacizumab cycles 35) and 25 tumors were evaluated. Radiologically significant (&gt; 20% from the baseline) tumor volume reduction was observed in 5 patients. Notably, in patients with bilateral VS, volume reduction occurred on only one side. Three patients demonstrated a significantly reduced growth rate and tumor stabilization. Hearing improvement was documented in 1 patient, while another experienced significant hearing decline. CONCLUSION: Bevacizumab therapy may contribute to tumor shrinkage and hearing stabilization in NF2 patients. However, treatment response is variable, with meaningful tumor reduction and hearing improvement observed only in a minority of cases.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30206 - Otorhinolaryngology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

European Archives of Oto-Rhino-Laryngology

ISSN

0937-4477

e-ISSN

—

Svazek periodika

282

Číslo periodika v rámci svazku

11

Stát vydavatele periodika

DE - Spolková republika Německo

Počet stran výsledku

7

Strana od-do

5947-5953

Kód UT WoS článku

001588665200001

EID výsledku v databázi Scopus

2-s2.0-105018490096